Creo Medical Reports 40% H1 Revenue Growth and Strong Cash Position

• SpydrBlade™ Flex FDA Clearance: Landing this in June expands their US GI toolkit, offering clinicians more flexibility right as reimbursement improves.
• MicroBlate™ Flex Gaining Traction: Commercial sales have started for lung tumour ablation, with more sites coming online. The initiation of the “ablate and resect” study at prestigious EU centres (Amsterdam UMC, Royal Brompton) is a vital step towards broader clinical adoption and evidence generation.
• Growing Clinical Evidence: The expanding library of papers and case studies using Creo devices is the quiet, essential work building long-term credibility with clinicians globally.

Partnership Power: The Micro-Tech Angle

The CME deal wasn’t just an exit; it was an entry into a powerful partnership. Reports of CME trading “above management expectations” are encouraging for Creo’s 49% stake and future dividends. More intriguingly, the active exploration of “strategic growth opportunities” together suggests potential synergies beyond Europe – perhaps leveraging Micro-Tech’s extensive distribution?

Outlook: Confidence Rooted in Execution

The Board’s confidence feels well-founded. They’ve delivered on:

• Revenue Growth: Hitting the H1 target.
• Cost Reduction: Significant savings achieved.
• Cash Generation: Balance sheet radically strengthened.
• Pipeline Progress: New products cleared, new indications advancing.

The path towards self-sustaining cashflows looks clearer than ever.

The October Capital Markets Event: One to Watch

Mark Thursday 9th October in the diary. Hosted at Deutsche Numis, this event is likely where Creo will unveil more granular details on:

• US commercial rollout post-CPT codes.
• MicroBlate™ Flex progress in lung.
• The evolving strategy with Micro-Tech.
• Updated financial trajectory towards breakeven.

Expect significant investor interest.

Final Thoughts: From Turnaround Story to Growth Story?

Creo’s H1 update is a compelling narrative of a company executing a difficult pivot. They’ve shed non-core burdens, tightened operations, secured crucial regulatory wins, and crucially, demonstrated their core technology can drive significant revenue growth. The leap in cash reserves provides vital breathing room and strategic optionality. While the journey to profitability continues, the pieces are falling into place with much greater certainty. The market will now be looking for H2 to deliver the expected acceleration and for the Capital Markets Event to provide the next chapter in what’s becoming a much more convincing growth story.